A study of the effect of cotreatment of taprostene (cg 4203), a novel stabilized prostacyclin analogue, with saruplase, a gene technologically produced unglycosylated single chain urokinase-type plasminogen activator (r-scuPA), in thrombolysis in vivo

  • Robert W. Groves

Student thesis: Doctoral ThesisPhD

Date of Award1990
Original languageEnglish
Awarding Institution
  • University of Bath

Cite this